NexImmune Past Earnings Performance
Past criteria checks 0/6
NexImmune's earnings have been declining at an average annual rate of -16.5%, while the Biotechs industry saw earnings growing at 12.7% annually.
Key information
-16.5%
Earnings growth rate
59.0%
EPS growth rate
| Biotechs Industry Growth | 17.0% |
| Revenue growth rate | n/a |
| Return on equity | -921.6% |
| Net Margin | n/a |
| Last Earnings Update | 31 Dec 2023 |
Recent past performance updates
No updates
Recent updates
NexImmune (NASDAQ:NEXI) Will Have To Spend Its Cash Wisely
Sep 07
Neximmune GAAP EPS of -$0.69 misses by $0.01
Aug 15NexImmune gains aftermarket on IND clearance for NEXI-003 to treat HPV-related cancers
Jul 14NexImmune: Selling For Under Cash Value
May 31Here's Why We're A Bit Worried About NexImmune's (NASDAQ:NEXI) Cash Burn Situation
May 26We're Keeping An Eye On NexImmune's (NASDAQ:NEXI) Cash Burn Rate
Dec 19Revenue & Expenses BreakdownBeta
How NexImmune makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Dec 23 | 0 | -32 | 13 | 16 |
| 30 Sep 23 | 0 | -44 | 14 | 30 |
| 30 Jun 23 | 0 | -49 | 14 | 35 |
| 31 Mar 23 | 0 | -57 | 15 | 42 |
| 31 Dec 22 | 0 | -63 | 16 | 47 |
| 30 Sep 22 | 0 | -61 | 16 | 45 |
| 30 Jun 22 | 0 | -61 | 16 | 46 |
| 31 Mar 22 | 0 | -57 | 16 | 42 |
| 31 Dec 21 | 0 | -51 | 16 | 37 |
| 30 Sep 21 | 0 | -45 | 15 | 30 |
| 30 Jun 21 | 0 | -39 | 14 | 23 |
| 31 Mar 21 | 0 | -35 | 12 | 19 |
| 31 Dec 20 | 0 | -33 | 10 | 18 |
| 30 Sep 20 | 0 | -30 | 9 | 17 |
| 31 Dec 19 | 0 | -23 | 6 | 15 |
Quality Earnings: NEXI is currently unprofitable.
Growing Profit Margin: NEXI is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: NEXI is unprofitable, and losses have increased over the past 5 years at a rate of 16.5% per year.
Accelerating Growth: Unable to compare NEXI's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: NEXI is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-8.9%).
Return on Equity
High ROE: NEXI has a negative Return on Equity (-921.57%), as it is currently unprofitable.